MaxCyte reported Q4 2024 revenue of $8.69 million, representing a -44.51% year-over-year decline and a +6.48% sequential gain from Q3 2024. The company posted a strong gross margin of 73.76% (gross profit of $6.41 million) but remains unprofitable at the operating level, delivering an operating loss of $12.90 million and a net loss of $10.60 million for the quarter. Despite the top-line weakness versus the prior-year period, QoQ improvements were evident in the operating metrics, with EBITDA of -$11.37 million and an improved operating margin of -1.48% ( versus -1.72% in Q3 2024). Management commentary from the earnings materials is not provided in the dataset, thus direct quotes could not be incorporated. On the balance sheet, MaxCyte maintains a robust liquidity position with cash and short-term investments totaling approximately $154.5 million and a net cash position of about -$9.85 million, offering ample runway to fund R&D and go-to-market initiatives as the company pursues adoption of its ExPERT platform family in cell therapy manufacturing. Near-term profitability remains a function of topline growth and operating leverage, while the company’s investment in R&D and SG&A points to a deliberate push to expand addressable markets and product capability. Valuation metrics imply stretched expectations relative to current earnings, with a price-to-sales ratio around 49x and a negative enterprise-value multiple historically, underscoring the market’s anticipation of longer-term growth rather than immediate profitability.